DETAILS, FICTION AND ANTI-ESTROGENS

At the end of their cycle, hematocrit stages experienced improved by 3%-point as opposed with baseline. The increase was not connected to more time use or better AAS dose. A cause for this may be that, over and above a particular degree of androgenic action, no additional boost of hematocrit happens: a ‘ceiling outcome’. Notably, whereas only f